44. Wegener granulomatosis Clinical trials / Disease details
Clinical trials : 92 / Drugs : 106 - (DrugBank : 27) / Drug target genes : 22 - Drug target pathways : 78
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03919435 (ClinicalTrials.gov) | March 27, 2019 | 5/4/2019 | Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis With Polyangiitis | Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis With Polyangiitis | Granulomatosis With Polyangiitis;Wegener Granulomatosis | Drug: Trimethoprim Sulfamethoxazole | University of Pennsylvania | NULL | Active, not recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |